Company: RNAC
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001453687-25-000075
Chunk: 84

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 84
---
            |     | 1/2/2024 |     |                  | 199,033 |     | $                                     | 19.656 |     | $                                  | 3,138,074 |     |                                                                                                                                                                                                                                                                                         | 6 | % |
| Blaine Davis                |     |            |     | 1/2/2024 |     |                  | 103,666 |     | $                                     | 19.656 |     | $                                  | 1,634,460 |     |                                                                                                                                                                                                                                                                                         | 6 | % |
| Metin Kurtoglu, M.D., Ph.D. |     |            |     | 1/2/2024 |     |                  |  65,499 |     | $                                     | 19.656 |     | $                                  | 1,032,697 |     |                                                                                                                                                                                                                                                                                         | 6 | % |
| Christopher Jewell, Ph.D.   |     |            |     | 1/2/2024 |     |                  |  33,265 |     | $                                     | 19.656 |     | $                                  |   524,476 |     |                                                                                                                                                                                                                                                                                         | 6 | % |

<div align='center'>49

Security Ownership of Certain Beneficial Owners and Management</div>

#### Common Stock
The following table sets forth certain information with respect to holdings of our Common Stock by (i) stockholders who beneficially owned more than 5% of the outstanding shares of our Common Stock, and (ii) each of our directors (which includes all nominees), each of our Named Executive Officers and all directors, director nominees and executive officers as a group, in both cases as of April 14, 2025, unless otherwise indicated. The number of shares beneficially owned by each stockholder is determined under rules issued by the SEC. Under these rules, beneficial ownership includes any shares as to which a person has sole or shared voting power or investment power. Applicable percentage ownership is based on 25,937,101 shares of Common Stock outstanding as of April 14, 2025. In computing the number of shares beneficially owned by a person and the percentage ownership of that person, shares of Common Stock subject to options, warrants or other rights held by such person that are currently exercisable or will become exercisable within 60 days of April 14, 2025 are considered outstanding, although these shares are not considered outstanding for purposes of computing the percentage